Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML)
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Robert Shepard, MD
Moleculin Biotech, Inc.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Medical University of Lodz
Lodz, Poland
- Szpital Kliniczny Przemienienia Pańskiego Uniwersytetu Medycznego Im. Karola Marcinkowskiego
Poznan, Poland
- Samodzielny Publiczny Szpital Kliniczny Nr 1 Im. Prof. Tadeusza Sokołowskiego W Szczecinie, Klinika Hematologii Z Oddziałem Transplantacji Szpiku
Szczecin, Poland
- Instytut Hematologii I Transfuzjologii, Klinika Hematologii
Warsaw, Poland
- Samodzielny Szpital Kliniczny Nr 1
Wroclaw, Poland
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 17 Dec 2018
- Primary completion
- 8 Feb 2022
- Completion
- 14 Feb 2022
- Last update posted
- 20 Jan 2023
- Registered enrollment
- 20
- Registry id
- NCT03388749
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.